Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2022-04-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
德勤华永会计师事务所（特殊普通合伙）关于成都先导药物开发股份有限公司2021年内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report' dated December 31, 2021. It is issued by Deloitte Huayong CPA firm and addresses the effectiveness of internal control over financial reporting for the company. The content includes auditor responsibilities, company responsibilities, and an audit opinion on internal control effectiveness. The document is a standalone audit report focused on internal control audit results, not a full annual report or financial statement. It does not appear to be a brief announcement or a certification letter but a formal audit report. Therefore, it fits the category of Audit Report / Information (AR). The document length is 4387 characters, which is consistent with a short audit report rather than a full annual report. Confidence is high due to clear audit report indicators and the presence of auditor opinion on internal control effectiveness. FY 2021
2022-04-28 Chinese
独立董事候选人声明（余海宗）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate, detailing qualifications, independence criteria, and compliance with regulatory requirements. It is a personal statement related to board membership candidacy, not a financial report, audit, or management discussion. It does not contain financial data or results, nor is it an announcement of voting results or a proxy solicitation. It is related to board/management information, specifically about a director candidate's qualifications and independence. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused on director candidacy declaration, fitting MANG rather than other categories.
2022-04-28 Chinese
成都先导药物开发股份有限公司关于董事会、监事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election and nomination of the company's board of directors and supervisory board members. It details the candidates, their qualifications, and the election process for the new board and supervisory board. There is no financial data, no discussion of financial results, no audit information, no legal proceedings, no merger or acquisition activity, and no mention of dividends or share transactions. The document is clearly about changes in the company's board and management structure. Therefore, it fits the category of Board/Management Information (MANG). The document length is sufficient and it is not merely an announcement of a report publication, but a substantive announcement of board changes.
2022-04-28 Chinese
成都先导药物开发股份有限公司2021年年度利润分配预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan announcement for the fiscal year 2021 by Chengdu Lead Drug Development Co., Ltd. It details the proposed cash dividend per share, total dividend amount, and the decision-making process including board and supervisory opinions. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. It is an announcement of dividend amount and payment details rather than a full annual report or earnings release. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is short (1510 characters), consistent with a dividend announcement rather than a full report.
2022-04-28 Chinese
成都先导药物开发股份有限公司2021年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report for the year 2021" from Chengdu Lead Drug Development Co., Ltd. It details the independent directors' duties, attendance at board and shareholder meetings, review of company operations, internal controls, compliance with laws and regulations, and their overall evaluation and outlook. The content focuses on governance, oversight, and the independent directors' role rather than financial results or audit opinions. It is not an annual report, audit report, or earnings release. It is a formal report by the independent directors on their activities and governance oversight for the year, which fits best under Board/Management Information (MANG) as it relates to board-level reporting and management oversight. The document length is 4340 characters, which is sufficient for a detailed report but not a brief announcement. Therefore, the classification is MANG with high confidence.
2022-04-28 Chinese
成都先导药物开发股份有限公司关于股东重庆渤溢新天股权投资基金合伙企业（有限合伙）减持计划时间届满暨减持结果公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement regarding the completion of a shareholder's share reduction plan. It details the shareholder's initial holdings, the planned reduction, the actual shares reduced, and the current holdings after the reduction. The document includes specific dates, share quantities, and percentages related to the shareholding changes. There is no financial performance data, audit information, or management discussion. The content focuses solely on the shareholder's transaction and the results of the share reduction plan. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2022-04-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.